US10369131B2 – August 6, 2019 – Ultrapure tetrahydrocannabinol-11-oic acids

Please complete the required fields.




Inventors :

Mark Tepper; Dean A. Frey; David Goeddel; Karl E. Reineke

Owner :

CORBUS PHARMACEUTICALS, INC., MASSACHUSETTS CORBUS PHARMACEUTICALS, INC., MASSACHUSETTS ALBANY MOLECULAR RESEARCH, INC., NEW YORK

Application Number :

US16198381

Document Number :

US10369131B2

Priority Date :

November 21, 2018

Filing Date :

November 21, 2018

Date of Grant/ Publication :

August 6, 2019

Class :

A61K31 / 352; A61K9 / 00

Abstract

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, Dupuytren’s contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring-wound healing abnormalities, post-operative adhesions, and reactive fibrosis.

Claim(s)

1. A method of ameliorating one or more symptoms of an inflammatory disease in a subject in need thereof, wherein the inflammatory disease is dermatomyositis, the method comprising administering to the subject a pharmaceutical composition comprising one or more cannabinoids, wherein said one or more cannabinoids comprise at least 98% (w/w) (6aR,10aR)-3-(1?,1?-dimethylheptyl)-?8-tetrahydro-cannabinol-9-carboxylic acid (ajulemic acid), or a pharmaceutically acceptable salt thereof, and wherein no significant antinociception is observed in a hot plate test of mice following oral administration to the mice of 10 mg/kg of said one or more cannabinoids.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login